Shanghai SIMR Biotechnology Co.,Ltd

中文 | EN

中文 EN

en2023 2022 2021 2020 2019 2018 2017 2016 2015 2014

Home > ABOUT SIMR > Milestones > 2021

2021

en2023 










In October, it completed the B+ round financing of nearly RMB200 million led by Zhang Jiang Haocheng and Zhang Jiang Haoheng

发布时间：2022年11月18日

In October, it completed the B+ round financing of nearly RMB200 million led by Zhang Jiang Haocheng and Zhang Jiang Haoheng

上一篇：In October, the second drug candidate, SR1375, successfully completed its first dose group administration in Australia. 下一篇：In December, SR419, the Company's first innovative drug to enter the clinical stage, was approved by the US Food and Drug Administration (FDA) for its international multi-center Phase II clinical stud